.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Cantor Fitzgerald
Julphar
Merck
Dow
Fuji
Accenture
Queensland Health
Fish and Richardson
Novartis

Generated: December 15, 2017

DrugPatentWatch Database Preview

NEXIUM IV Drug Profile

« Back to Dashboard

When do Nexium Iv patents expire, and what generic alternatives are available?

Nexium Iv is a drug marketed by Astrazeneca Pharms and is included in one NDA.

The generic ingredient in NEXIUM IV is esomeprazole sodium. There are sixty-nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the esomeprazole sodium profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Astrazeneca PharmsNEXIUM IVesomeprazole sodiumINJECTABLE;INTRAVENOUS021689-001Mar 31, 2005DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Astrazeneca PharmsNEXIUM IVesomeprazole sodiumINJECTABLE;INTRAVENOUS021689-002Mar 31, 2005APRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NEXIUM IV

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca PharmsNEXIUM IVesomeprazole sodiumINJECTABLE;INTRAVENOUS021689-001Mar 31, 2005► Subscribe► Subscribe
Astrazeneca PharmsNEXIUM IVesomeprazole sodiumINJECTABLE;INTRAVENOUS021689-002Mar 31, 2005► Subscribe► Subscribe
Astrazeneca PharmsNEXIUM IVesomeprazole sodiumINJECTABLE;INTRAVENOUS021689-002Mar 31, 2005► Subscribe► Subscribe
Astrazeneca PharmsNEXIUM IVesomeprazole sodiumINJECTABLE;INTRAVENOUS021689-001Mar 31, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for NEXIUM IV

Drugname Dosage Strength RLD Submissiondate
esomeprazole sodiumFor Injection20 mg/vial and 40 mg/vialNexium IV11/23/2009

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
QuintilesIMS
Dow
UBS
Healthtrust
McKinsey
Accenture
Merck
Federal Trade Commission
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot